RGEN
Repligen Corporation
Is RGEN Halal?
Bioprocessing products for life sciences with permissible business.
What You Should Know
Repligen provides bioprocessing equipment and consumables for biopharmaceutical manufacturing. Its March 31, 2026 Form 10-Q reports $2,930.772 million of assets, $546.585 million of convertible debt, $582.650 million of cash, $201.881 million of marketable securities, $151.552 million of receivables and $194.255 million of quarterly revenue. Debt/assets is 18.65%, liquidity/assets is 26.77% and receivables-plus-cash/assets is 25.05%; the examined MSCI and Malaysia ratios pass, while FTSE remains incomplete because investment income is not separately classified as interest income.
⚠️ Concerns
- •Biopharmaceutical and clinical customer end uses
- •Convertible debt
- •Investment income is not separately classified as interest income
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
546.585 / 2,930.772
784.531 / 2,930.772
734.202 / 2,930.772
- Financial
- Incomplete
- Overall
- Incomplete
Debt/assets is 18.65%, liquidity/assets is 26.77% and receivables-plus-cash/assets is 25.05%, below the examined FTSE limits; interest income is not separately quantified.
- Financial
- Pass
- Overall
- Pass
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI total-assets limits; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and liquidity/assets pass the examined Malaysia limits; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored and standalone interest income is unavailable; filing-based ratios remain documented.
Business-activity disclosure
Repligen provides bioprocessing equipment, consumables and related technologies for biopharmaceutical manufacturing. The core activity is generally permissible.
Limitation: The filing does not allocate every biopharma, clinical, research or customer end use into a scholar-approved prohibited-revenue numerator.
Purification
Repligen discloses $6.342 million of investment income but does not separately quantify interest income or provide a scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from Repligen's March 31, 2026 Form 10-Q values reported in thousands.
- Convertible senior notes due 2028 are $546.585 million net; operating leases and contingent consideration are excluded.
- Cash is $582.650 million and marketable securities are $201.881 million; the latter is used as the interest-bearing-securities proxy.
- Accounts receivable are $151.552 million net; first-quarter total revenue is $194.255 million.
- The filing reports investment income of $6.342 million but does not separately quantify interest income, so the income input is unavailable.
- Bioprocessing equipment, consumables and life-sciences manufacturing support are treated as generally permissible; customer end uses require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →